title: Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
abstract: We have examined the antipneumococcal mechanisms of a series of novel fluoroquinolones that are identical to ciprofloxacin except for the addition of a benzenesulfonylamido group to the C-7 piperazinyl ring. A number of these derivatives displayed enhanced activity against Streptococcus pneumoniae strain 7785, including compound NSFQ-105, bearing a 4-(4-aminophenylsulfonyl)-1-piperazinyl group at C-7, which exhibited an MIC of 0.06 to 0.125 microg/ml compared with a ciprofloxacin MIC of 1 microg/ml. Several complementary approaches established that unlike the case for ciprofloxacin (which targets topoisomerase IV), the increased potency of NSFQ-105 was associated with a target preference for gyrase: (i) parC mutants of strain 7785 that were resistant to ciprofloxacin remained susceptible to NSFQ-105, whereas by contrast, mutants bearing a quinolone resistance mutation in gyrA were four- to eightfold more resistant to NSFQ-105 (MIC of 0.5 microg/ml) but susceptible to ciprofloxacin; (ii) NSFQ-105 selected first-step gyrA mutants (MICs of 0.5 microg/ml) encoding Ser-81-to-Phe or -Tyr mutations, whereas ciprofloxacin selects parC mutants; and (iii) NSFQ-105 was at least eightfold more effective than ciprofloxacin at inhibiting DNA supercoiling by S. pneumoniae gyrase in vitro but was fourfold less active against topoisomerase IV. These data show unequivocally that the C-7 substituent determines not only the potency but also the target preference of fluoroquinolones. The importance of the C-7 substituent in drug-enzyme contacts demonstrated here supports one key postulate of the Shen model of quinolone action.
authors.affiliation: Molecular Genetics Group, Department of Biochemistry, St. George's Hospital Medical School, University of London, London SW17 ORE, United Kingdom.
authors.forename: F L
authors.initials: FL
authors.lastname: Alovero
authors.forename: X S
authors.initials: XS
authors.lastname: Pan
authors.forename: J E
authors.initials: JE
authors.lastname: Morris
authors.forename: R H
authors.initials: RH
authors.lastname: Manzo
authors.forename: L M
authors.initials: LM
authors.lastname: Fisher
mesh_terms: D000890:Anti-Infective Agents / Q000737:chemistry / Q000494:pharmacology*; D002384:Catalysis; D002939:Ciprofloxacin / Q000737:chemistry / Q000494:pharmacology*; D027081:DNA Gyrase; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism; D015195:Drug Design; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009154:Mutation; D015363:Quinolones / Q000494:pharmacology; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000201:enzymology; D013449:Sulfonamides / Q000737:chemistry*; D059005:Topoisomerase II Inhibitors; D000096926:Benzenesulfonamides
chemical_list: D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D027081:DNA Gyrase; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II; D024841:Fluoroquinolones; D015363:Quinolones; D013449:Sulfonamides; D059005:Topoisomerase II Inhibitors; D000096926:Benzenesulfonamides; C091356:NSFQ-105